Eslicarbazepine acetate as a therapeutic option in a patient with carbamazepine-induced rash and HLA-A*31:01.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Seizure

• Publication date

  2017-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.seizure.2017.02.019PMID 28340402
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2016cited by this paper
• Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus

  2015cited by this paper
• Recommendations for HLA‐B*15:02 and HLA‐A*31:01 genetic testing to reduce the risk of carbamazepine‐induced hypersensitivity reactions

  2014cited by this paper
• Pharmacokinetics and drug interactions of eslicarbazepine acetate

  2012cited by this paper
• Eslicarbazepine acetate in the management of refractory bipolar disorder.

  2012cited by this paper

• A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)

  2024cites this paper
• [EXPRESS] Trigeminal Neuralgia: an overview from pathophysiology to pharmacological treatments.

  2020cites this paper
• The tolerability and safety profile of eslicarbazepine acetate in neurological disorders.

  2020cites this paper
• Epidemiology of Severe Cutaneous Adverse Drug Reaction and Its HLA Association among Pediatrics

  2019cites this paper
• Eslicarbazepine acetate in epilepsies with focal and secondary generalised seizures: systematic review of current evidence

  2018cites this paper
• Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy

  2018cites this paper
• Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany

  2017cites this paper